Arrowhead gets a big Wall Street glow-up

Wall Street just cranked up the volume

Morgan Stanley decided Arrowhead Pharmaceuticals deserves a louder cheer, lifting its rating to Overweight and jacking the price target to $100 from $78. That’s not exactly a subtle tap on the shoulder — it’s more like Wall Street turning the car stereo from 6 to 11.

Why you should care

Arrowhead closed Monday at $69.25, so the new target implies plenty of upside if the market buys the thesis. For a biotech name, that kind of analyst upgrade can matter a lot because sentiment moves fast, and sentiment is basically rocket fuel when a stock already has momentum.

The bigger analyst tape

This article is really a roundup of Tuesday’s analyst action, with several other names getting price-target tweaks too. But Arrowhead is the headline act here, and the upgrade stands out because it pairs a higher target with a rating bump — the classic one-two punch that can pull more buyers into the story.

Big picture: when analysts get more bullish on a biotech, the stock doesn’t need a miracle to run — sometimes it just needs a nudge and a cleaner narrative.